Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000297840 | SCV000446281 | likely benign | Glycogen storage disease, type IV | 2018-01-13 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. |
Illumina Laboratory Services, |
RCV000357256 | SCV000446282 | likely benign | Adult polyglucosan body disease | 2018-01-13 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. |
Labcorp Genetics |
RCV000966281 | SCV001113579 | benign | Glycogen storage disease, type IV; Glycogen storage disease IV, classic hepatic | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000297840 | SCV001653468 | uncertain significance | Glycogen storage disease, type IV | 2021-05-18 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001354590 | SCV001795583 | likely benign | not provided | 2019-11-14 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001354590 | SCV002496842 | likely benign | not provided | 2022-05-01 | criteria provided, single submitter | clinical testing | GBE1: BP4, BS2 |
Natera, |
RCV000297840 | SCV001460899 | benign | Glycogen storage disease, type IV | 2020-06-04 | no assertion criteria provided | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV001354590 | SCV001549239 | likely benign | not provided | no assertion criteria provided | clinical testing | The GBE1 p.Arg679Cys variant was not identified in the literature but was identified in dbSNP (ID: rs202158511) and ClinVar (classified as uncertain significance by Illumina and as benign by Invitae). The variant was identified in control databases in 145 of 273980 chromosomes (2 homozygous) at a frequency of 0.0005292 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: South Asian in 121 of 29454 chromosomes (freq: 0.004108), East Asian in 4 of 19138 chromosomes (freq: 0.000209), Latino in 7 of 34592 chromosomes (freq: 0.000202), Other in 1 of 6970 chromosomes (freq: 0.000144) and European (non-Finnish) in 12 of 125122 chromosomes (freq: 0.000096), but was not observed in the African, Ashkenazi Jewish, or European (Finnish) populations. The p.Arg679 residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. |